Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05394233 | Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC | unknown | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05387044 | SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors | unknown | Phase 2 | 28 | Zhejiang Cancer HospitalOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT05085054 | Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT) | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | May 20, 2022 | clinicaltrials |
| NCT05380271 | Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC | unknown | Phase 2 | 60 | Gang WuOTHER | 0 | May 18, 2022 | clinicaltrials |
| NCT05360979 | A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC | unknown | Phase 2 | 42 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | May 4, 2022 | clinicaltrials |
| NCT02562963 | Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Minghui ZhangOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT04878107 | SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy(SABRE) | unknown | Phase 2 | 88 | Wuhan UniversityOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT05351320 | WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC | unknown | Phase 2 | 40 | Jinming YuOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT05329298 | A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 90 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT01470716 | Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations | unknown | Phase 2 | 26 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03612154 | Study of Lorlatinib in ROS1 Rearranged NSCLC | unknown | Phase 2 | 35 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03808480 | Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% | unknown | Phase 2 | 22 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT04040361 | Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY) | unknown | Phase 2 | 24 | Masahiro TsuboiOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05306847 | Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer | unknown | Phase 2 | 93 | Peking Union Medical College HospitalOTHER | 0 | Apr 1, 2022 | clinicaltrials |
| NCT05236608 | A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC(ADIVO Lung) | unknown | Phase 1 / Phase 2 | 53 | National University Hospital, SingaporeOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT05287386 | A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy | unknown | Phase 2 | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05284994 | TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 160 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT04690686 | Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC). | unknown | Phase 2 | 24 | Immunicom IncINDUSTRY | 1 | Mar 8, 2022 | clinicaltrials |
| NCT05267392 | Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy(IDEAR) | unknown | Phase 1 / Phase 2 | 30 | Instituto Portugues de Oncologia, Francisco Gentil, PortoOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT04956146 | Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer | unknown | Phase 2 | 46 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05252091 | An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC | unknown | Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 0 | Feb 23, 2022 | clinicaltrials |
| NCT03801200 | Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC | unknown | Phase 2 | 90 | Hubei Cancer HospitalOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT05207904 | Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases | unknown | Phase 2 | 41 | Sun Yat-sen UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05209256 | Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC | unknown | Phase 2 / Phase 3 | 90 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 0 | Jan 26, 2022 | clinicaltrials |
| NCT05065398 | A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation | unknown | Phase 2 | 20 | Shanghai Henlius BiotechINDUSTRY | 1 | Jan 21, 2022 | clinicaltrials |
| NCT05165355 | Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma(ATHEM) | unknown | Phase 2 | 90 | Tongji UniversityOTHER | 1 | Jan 18, 2022 | clinicaltrials |
| NCT05192681 | Tislelizumab as Cross-line Treatment for Advanced NSCLC | unknown | Phase 2 | 35 | Fujian Cancer HospitalOTHER_GOV | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05177497 | SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC | unknown | Phase 2 | 19 | Shanghai Chest HospitalOTHER | 0 | Jan 4, 2022 | clinicaltrials |
| NCT05170581 | Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer | unknown | Phase 2 | 30 | The Second Affiliated Hospital of Shandong First Medical UniversityOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05167851 | The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer | unknown | Phase 2 | 68 | Yonsei UniversityOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT04989322 | Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC | unknown | Phase 2 | 46 | Dr Joanne CHIUOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT05141786 | A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC). | unknown | Phase 2 | 100 | Shanghai Miracogen Inc.INDUSTRY | 1 | Dec 2, 2021 | clinicaltrials |
| NCT02897479 | A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer | unknown | Phase 2 | 76 | Hutchison Medipharma LimitedINDUSTRY | 1 | Nov 30, 2021 | clinicaltrials |
| NCT05132777 | Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer | unknown | Phase 2 | 155 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Nov 24, 2021 | clinicaltrials |
| NCT04405674 | Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC | unknown | Phase 2 | 120 | Shanghai Chest HospitalOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT02824952 | Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC | unknown | Phase 2 | 40 | Shaare Zedek Medical CenterOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT05117138 | Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors | unknown | Phase 1 / Phase 2 | 39 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Nov 11, 2021 | clinicaltrials |
| NCT05079022 | ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas | unknown | Phase 1 / Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT05055167 | Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC | unknown | Phase 2 | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT05055583 | Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC | unknown | Phase 2 | 30 | Tang-Du HospitalOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT05044728 | Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest. | unknown | Phase 2 | 80 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT02330367 | Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC | unknown | Phase 1 / Phase 2 | 368 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Sep 10, 2021 | clinicaltrials |
| NCT04291092 | Camrelizumab Combined With Local Treatment in NSCLC Patients With BM | unknown | Phase 2 | 63 | Zhejiang Cancer HospitalOTHER | 1 | Sep 10, 2021 | clinicaltrials |
| NCT04755738 | Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer(MWA) | unknown | Phase 2 | 234 | Qianfoshan HospitalOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT05034055 | Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer(SKYROCKET) | unknown | Phase 2 | 45 | Yonsei UniversityOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT04943029 | Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC(NEOSUN) | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT05024266 | Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma(TACT) | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT04586465 | Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC(DYNAPET) | unknown | Phase 2 | 23 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT05016544 | Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Aug 23, 2021 | clinicaltrials |
Data updated 23 days agoSource updated May 27, 2022source: clinicaltrials